Skip to content

US · STIM · MEDICAL - DEVICES

Neuronetics, Inc. (STIM) intrinsic value and stock valuation

$1.25as of 2026-11-21 · Mkt cap 163.53M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Neuronetics, Inc. DCF and intrinsic value

InvestorsCraft values STIM with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from STIM’s statements →

Neuronetics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Malvern, PA 19355 neurostar.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$149.2M+24.8% 5y CAGRd
20162025
Net income
-$-39M
20162025
Free cash flow
-$-21.18M
20162025
Total equity
$26.2M+0.6% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$149.2M$74.9M$71.4M$65.2M$55.3M
Operating income-$-31.44M-$-34.56M-$-30.55M-$-35.11M-$-27.56M
Net income-$-39M-$-43.71M-$-30.19M-$-37.16M-$-31.19M
EPSd-$-591.36K-$-1.38M-$-1.05M-$-1.38M-$-1.22M
Operating cash flow-$-20.37M-$-31M-$-32.04M-$-30.74M-$-27.98M
Capital expenditure-$-800K-$-1.47M-$-2.37M-$-3.27M-$-2.35M
Free cash flow-$-21.18M-$-32.46M-$-34.41M-$-34.01M-$-30.34M
Total assets$141.6M$140.9M$115.8M$116.9M$141.2M
Total debt$90.3M$82.6M$62.5M$39.7M$39.5M
Net debt$56.2M$63.2M$2.8M-$-30.59M-$-54.6M
Total equity$26.2M$31.8M$34.2M$57.1M$85.2M
Cash and short-term investments$34.4M$19.7M$60.6M$71.9M$96.3M
Income statement
20252024202320222021
Revenue$149.2M$74.9M$71.4M$65.2M$55.3M
Cost of revenue$76.9M$20.7M$19.6M$15.5M$11.7M
Gross profit$72.3M$54.2M$51.7M$49.7M$43.7M
Research and development expenses$6.58M$12.8M$9.52M$9.34M$7.92M
Selling, general and administrative expenses$97.2M$76M$72.7M$75.5M$63.3M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$103.7M$88.7M$82.3M$84.8M$71.2M
Cost and expenses$180.6M$109.5M$101.9M$100.3M$82.9M
Interest income$0.00$0.00$20K$0.00$0.00
Interest expense$8.41M$7.29M$5.42M$3.6M$3.3M
Depreciation and amortization$3.46M$2.07M$2.01M$1.65M$1.06M
Ebitda-$-27.12M-$-34.37M-$-22.76M-$-31.96M-$-26.81M
Operating income-$-31.44M-$-34.56M-$-30.55M-$-35.11M-$-27.56M
Total other income/expenses, net-$-7.56M-$-9.18M$360K-$-2.1M-$-3.61M
Income before tax-$-39M-$-43.74M-$-30.19M-$-37.21M-$-31.17M
Income tax expense$0.00-$-10K-$-20K$0.00$0.00
Net income-$-39M-$-43.71M-$-30.19M-$-37.16M-$-31.19M
Weighted average shares outstanding$66M$31.7M$28.7M$26.9M$25.5M
Weighted average diluted shares outstanding$66M$31.7M$28.7M$26.9M$25.5M
Balance sheet
20252024202320222021
Cash and short-term investments$34.4M$19.7M$60.6M$71.9M$96.3M
Net receivables$16.9M$24.3M$17.8M$13.8M$7.78M
Inventory$4.33M$4.25M$8.09M$8.9M$6.56M
Total current assets$61.6M$58.1M$93.8M$98.8M$115.3M
Property, plant and equipment, net$28M$33.3M$4.78M$5.32M$5.1M
Goodwill and intangible assets$41.8M$38.2M$0.00$0.00$0.00
Long-term investments$250K$90K$660K$1.22M$1.7M
Total non-current assets$80M$82.8M$22M$18.1M$25.9M
Total assets$141.6M$140.9M$115.8M$116.9M$141.2M
Accounts payable$10.7M$11.1M$4.75M$2.43M$4.3M
Short-term debt$5.56M$4.79M$840K$14M$670K
Deferred revenue$750K$970K$1.62M$1.98M$2.5M
Total current liabilities$30.5M$31.3M$19.8M$33.2M$15.7M
Long-term debt$84.7M$77.8M$61.6M$25.8M$38.9M
Deferred revenue, non-current$50K$0.00$200K$830K$1.47M
Total non-current liabilities$84.8M$77.8M$61.8M$26.6M$40.3M
Capital lease obligations$18.9M$27.5M$3.19M$3.79M$4.21M
Total liabilities$115.3M$109.1M$81.6M$59.8M$56.1M
Common stock$690K$560K$290K$270K$260K
Retained earnings-$-458.79M-$-419.79M-$-376.08M-$-345.89M-$-308.73M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$26.2M$31.8M$34.2M$57.1M$85.2M
Total investments$470K$290K$1.57M$2.76M$3.9M
Total debt$90.3M$82.6M$62.5M$39.7M$39.5M
Net debt$56.2M$63.2M$2.8M-$-30.59M-$-54.6M
Cash flow statement
20252024202320222021
Net income-$-39.13M-$-43.73M-$-30.19M-$-37.16M-$-31.19M
Depreciation and amortization$3.46M$2.07M$2.01M$1.65M$1.06M
Stock-based compensation$6.85M$5.6M$7.32M$8.75M$7.87M
Change in working capital$6.58M-$-6.81M-$-14.1M-$-5.12M-$-6.64M
Accounts receivable$3.54M-$-3.73M-$-8.83M-$-6.66M-$-3.05M
Inventory-$-400K$3.15M-$-1.1M-$-2.59M-$-3.44M
Accounts payable-$-1.75M-$-1.99M$2.03M-$-1.97M$280K
Net cash provided by operating activities-$-20.37M-$-31M-$-32.04M-$-30.74M-$-27.98M
Investments in property, plant and equipment-$-800K-$-1.47M-$-2.37M-$-3.27M-$-2.35M
Acquisitions, net$0.00-$-2.55M$0.00$0.00$0.00
Net cash used for investing activities-$-800K-$-2.41M-$-1.32M$6.73M-$-9.84M
Common stock issued$26.8M$0.00$0.00$0.00$81M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$35.9M-$-6.81M$22.7M$210K$83M
Net change in cash$14.7M-$-40.22M-$-10.66M-$-23.8M$45.2M
Cash at end of period$34.1M$19.5M$59.7M$70.3M$94.1M
Operating cash flow-$-20.37M-$-31M-$-32.04M-$-30.74M-$-27.98M
Capital expenditure-$-800K-$-1.47M-$-2.37M-$-3.27M-$-2.35M
Free cash flow-$-21.18M-$-32.46M-$-34.41M-$-34.01M-$-30.34M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Neuronetics, Inc.

        Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.

        CEO
        Daniel L. Reuvers
        Employees
        658
        Beta
        1.06

        Explore

        Frequently asked questions

        What is the intrinsic value of Neuronetics, Inc. (STIM)?

        InvestorsCraft does not currently publish an intrinsic value for STIM. How the IC value is calculated.

        Is STIM undervalued?

        InvestorsCraft does not publish an undervaluation signal for STIM at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.